In Vitro Evaluation of the Medtronic™ Cardioplegia Safety System®

Abstract

Myocardial preservation demands the precise and accurate delivery of cardioplegic solutions to provide nutritive delivery and metabolic waste removal. The purpose of this study was to evaluate the performance characteristics of the Medtronic® CSS™ Cardioplegia Safety System in an in vitro setting. The CSS™ was evaluated under the following conditions: blood to crystalloid ratios of 1:0, 1:1, 4:1, 8:1, 0:1; potassium concentrations of 10, 20, and 40 mEq L−1; volumetric delivery collection at 100, 250, 500, 750, and 990 mL/min; pressure accuracy at 100 and 300 mmHg; and system safety mechanisms. Measured and predicted values from the CSS were compared using one way ANOVA, with statistical significance accepted at p ≤ 0.05. The measured values for the tested ratios and volume collections were all within the manufacturer’s technical parameters. Potassium concentration results were all within expected values except at 100 mL/min, where the measured value of 17.1 ± 2.1 mmol was lower than the expected 20.0 ± 0.2 mmol (p < .034). As flow rates changed, the CSS line pressure error was constant (0.5 to 3.7%), and the only significant difference was observed at 100 mmHg, 500 mL/min (102.3 ± 1.7 vs. 100.0 ± 0.0 mmHg, P < .003). The device performed accurately and reliably under all simulated safety conditions, including bubble detection, over pressurization and battery backup. In conclusion, the performance of the CSS was within the manufacturer’s specifications for the majority of the tested conditions and operated safely when challenged under varying conditions.